Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA.
InsilicAll, Sao Paulo, SP 04571-010, Brazil.
Toxicol Sci. 2022 Sep 24;189(2):250-259. doi: 10.1093/toxsci/kfac078.
In the United States, a pre-market regulatory submission for any medical device that comes into contact with either a patient or the clinical practitioner must include an adequate toxicity evaluation of chemical substances that can be released from the device during its intended use. These substances, also referred to as extractables and leachables, must be evaluated for their potential to induce sensitization/allergenicity, which traditionally has been done in animal assays such as the guinea pig maximization test (GPMT). However, advances in basic and applied science are continuously presenting opportunities to employ new approach methodologies, including computational methods which, when qualified, could replace animal testing methods to support regulatory submissions. Herein, we developed a new computational tool for rapid and accurate prediction of the GPMT outcome that we have named PreS/MD (predictor of sensitization for medical devices). To enable model development, we (1) collected, curated, and integrated the largest publicly available dataset for GPMT results; (2) succeeded in developing externally predictive (balanced accuracy of 70%-74% as evaluated by both 5-fold external cross-validation and testing of novel compounds) quantitative structure-activity relationships (QSAR) models for GPMT using machine learning algorithms, including deep learning; and (3) developed a publicly accessible web portal integrating PreS/MD models that can predict GPMT outcomes for any molecule of interest. We expect that PreS/MD will be used by both industry and regulatory scientists in medical device safety assessments and help replace, reduce, or refine the use of animals in toxicity testing. PreS/MD is freely available at https://presmd.mml.unc.edu/.
在美国,任何与患者或临床医生接触的医疗器械的上市前监管提交都必须包括对设备在预期使用过程中可能释放的化学物质进行充分的毒性评估。这些物质也称为浸出物和可沥滤物,必须评估其潜在的致敏/变应原性,这在传统上是通过动物试验如豚鼠最大剂量试验(GPMT)来完成的。然而,基础和应用科学的进步不断为采用新的方法学提供机会,包括计算方法,这些方法在经过合格验证后,可以替代动物试验方法来支持监管提交。在此,我们开发了一种新的计算工具,用于快速准确地预测 GPMT 结果,我们将其命名为 PreS/MD(医疗器械致敏预测器)。为了实现模型开发,我们(1)收集、整理和整合了最大的公开 GPMT 结果数据集;(2)成功地使用机器学习算法(包括深度学习)为 GPMT 开发了具有外部预测能力的定量构效关系(QSAR)模型(通过 5 倍外部交叉验证和新化合物的测试评估,平衡准确性为 70%-74%);(3)开发了一个公共访问的门户网站,集成了 PreS/MD 模型,可以预测任何感兴趣分子的 GPMT 结果。我们预计 PreS/MD 将被医疗器械安全评估的行业和监管科学家使用,并有助于替代、减少或改进毒性测试中的动物使用。PreS/MD 可在 https://presmd.mml.unc.edu/ 免费获得。